A step closer to meeting the threat of avian influenza

PLoS Medicine

Volumn 3, Issue 9, 2006, Pages 1463-1464

  Schultz Cherry, Stacey ^a   McCullers, Jonathan A ^b  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOLOGICAL ADJUVANT; INACTIVATED VIRUS VACCINE; INFLUENZA VACCINE; LIVE VACCINE; VIRUS ANTIBODY;

ANTIBODY RESPONSE; ANTIBODY TITER; AVIAN INFLUENZA; DRUG EFFICACY; DRUG MANUFACTURE; DRUG RESPONSE; DRUG SAFETY; GENE SEQUENCE; GENETIC PROCEDURES; HOST PATHOGEN INTERACTION; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; INFECTION PREVENTION; INFLUENZA VACCINATION; INFLUENZA VIRUS A; MORTALITY; NONHUMAN; PROVOCATION TEST; SHORT SURVEY; VACCINE PRODUCTION; VIRUS GENE; VIRUS REPLICATION; VIRUS STRAIN; ANIMAL; BIRD; EPIDEMIC; GENETICS; IMMUNOLOGY; INFLUENZA; INFLUENZA VIRUS A H5N1; REVIEW;

ANIMALS; BIRDS; DISEASE OUTBREAKS; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA IN BIRDS; INFLUENZA, HUMAN;

EID: 33749011720     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.0030375     Document Type: Short Survey

References (13)

1. Beigel JH, Farrar J, Han AM, Hayden FG, Hyer R, et al. (2005) Avian influenza A (H5N1) infection in humans. N Engl J Med 353: 1374-1385.
2. Palese P (2006) Making better influenza virus vaccines? Emerg Infect Dis 12: 61-65.
3. Nicholson KG, Colegate AE, Podda A, Stephenson I, Wood J, et al. (2001) Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: A randomised trial of two potential vaccines against H5N1 influenza. Lancet 357: 1937-1943.
4. Treanor JJ, Wilkinson BE, Masseoud F, Hu-Primmer J, Battaglia R, et al. (2001) Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 19: 1732-1737.
5. Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M (2006) Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 354: 1343-1351.
6. Li S, Liu C, Klimov A, Subbarao K, Perdue ML, et al. (1999) Recombinant influenza A virus vaccines for the pathogenic human A/Hong Kong/97 (H5N1) viruses. J Infect Dis 179: 1132-1138.
7. Subbarao K, Chen H, Swayne D, Mingay L, Fodor E, et al. (2003) Evaluation of a genetically modified reassortant H5N1 influenza A virus vaccine candidate generated by plasmid-based reverse genetics. Virology 305: 192-200.
8. Webby RJ, Perez DR, Coleman JS, Guan Y, Knight JH, et al. (2004) Responsiveness to a pandemic alert: Use of reverse genetics for rapid development of influenza vaccines. Lancet 363: 1099-1103.
9. Wong SS, Yuen KY (2006) Avian influenza virus infections in humans. Chest 129: 156-168.
10. Belshe RB, Gruber WC (2001) Safety, efficacy and effectiveness of cold-adapted, live, attenuated, trivalent, intranasal influenza vaccine in adults and children. Philos Trans R Soc Lond B Biol Sci 356: 1947-1951.
11. Murphy BR, Coelingh K (2002) Principles underlying the development and use of live attenuated cold-adapted influenza A and B virus vaccines. Viral Immunol 15: 295-323.
12. Chen H, Matsuoka Y, Swayne D, Chen Q, Cox NJ, et al. (2003) Generation and characterization of a cold-adapted influenza A H9N2 reassortant as a live pandemic influenza virus vaccine candidate. Vaccine 21: 4430-4436.
13. Suguitan AL Jr., McAuliffe J, Mills KL, Jin H, Duke G, et al. (2006) Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets. PLoS Med 3: e360. DOI: 10.1371/journal.pmed.0030360